Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease

Summary

The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging (MRI) data. Additionally, the study aims to analyze the potential impact of device-based interventions, pharmacological therapy, and lifestyle modifications on disease progression.

Conditions

• Heart Valve Disease
• Mitral Valve (MV) Regurgitation
• Mitral Valve Disease
• Mitral Valve Stenosis
• Aortic Valve Disease
• Aortic Valve Stenosis
• Tricuspid Valve Disease
• Tricuspid Valve Regurgitation
• Aortic Valve Regurgitation
• Pulmonary Valve Disease
• Transcatheter Valve Replacement
• Transcatheter Aortic Valve Replacement (TAVR)
• Transcatheter Pulmonary Valve Replacement (TPVR)
• Transcatheter Edge-to-edge Repair

Sponsors & Collaborators

• Army Medical Center of PLA

  collaborator OTHER_GOV

• Huaxi Hospital

  collaborator OTHER

• Fuwai Yunnan Cardiovascular Hospital

  collaborator OTHER

• People's Hospital of Xinjiang Uygur Autonomous Region

  collaborator OTHER

• Second Xiangya Hospital of Central South University

  collaborator OTHER

• Xiangya Hospital of Central South University

  collaborator OTHER

• The General Hospital of Northern Theater Command

  collaborator OTHER

• Chinese Academy of Medical Sciences, Fuwai Hospital

  collaborator OTHER

• Fujian Provincial Hospital

  collaborator OTHER

• Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  collaborator OTHER

• The Affiliated Hospital of Qingdao University

  collaborator OTHER

• Renmin Hospital of Wuhan University

  collaborator OTHER

• The First Affiliated Hospital of Air Force Medicial University

  collaborator OTHER

• Navy General Hospital, Beijing

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-06-01

Primary Completion

2027-12-31

Completion

2030-05-31

Countries

• China

Study Locations